Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
Genmab A/S (GNMSF) Q4 2019 Earnings Conference Call February 19, 2020 12:00 PM ET Company Participants Jan van de Winkel - Chief Executive Officer David Eatwell - Chief Financial Officer Anthony Pagano - American Senior Vice President, Finance & Corporate Development Confe...
The following slide deck was published by Genmab A/S in conjunction with their 2019 Q4 earnings Read more ...
Genmab A/S (GNMSF) Q3 2019 Results Conference Call November 06, 2019 12:00 PM ET Company Participants Jan van de Winkel - President and CEO David Eatwell - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets Wimal Kapadia - Bernstein Michael Schmidt - Gug...
Genmab A/S ( OTCPK:GNMSF ) announces that the European advisory group CHMP has adopted a positive opinion recommending approval of licensee Johnson & Johnson's (NYSE: JNJ ) Darzalex (daratumumab), combined with lenalidomide and dexamethasone, for treating newly diagnosed adult patients...
Genmab A/S (GNMSF) Q2 2019 Results Conference Call August 14, 2019 12:00 PM ET Company Participants Jan van de Winkel - President and CEO David Eatwell - CFO Conference Call Participants Kennen MacKay - RBC Capital Markets James Quigley - J.P. Morgan Wimal Kapadia - Berns...
The following slide deck was published by Genmab A/S in conjunction with their 2019 Q2 earnings Read more ...
Genmab ( OTCPK:GNMSF ) prices its IPO of 28.5M (from 27.8M) American Depositary Shares (ADSs) at $17.75 per ADS, each representing 1/10 of an ordinary share. More news on: Genmab A/S, Healthcare stocks news, IPO News, Read more ...
Genmab A/S ( OTCPK:GNMSF ) is up 2% in Europe in reaction to Johnson & Johnson's Q2 results that included a 51% jump in Darzalex (daratumumab) sales to $774M. More news on: Genmab A/S, Genmab A/S, Healthcare stocks news, Stocks on the move, Read more ...
Genmab A/S ( OTCPK:GNMSF ) announces that licensee Janssen Biotech, a unit of Johnson & Johnson ( JNJ -5.2% ), has filed a marketing application with the FDA seeking approval for a subcutaneously administered formulation of multiple myeloma med Darzalex (daratumumab). More news on:...
Genmab A/S ( OTCPK:GNMSF -2.3% ) announces that a Phase 2 clinical trial, GRIFFIN , evaluating licensee Johnson & Johnson ( JNJ +0.3% ) unit Janssen Biotech's Darzalex (daratumumab), combined with Celgene's Revlimid (lenalidomide), Takeda's Velcade (bortezomib) and dexamethas...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...